Adverum Biotechnologies Stock Alpha and Beta Analysis
| ADVM Stock | USD 4.36 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Adverum Biotechnologies. It also helps investors analyze the systematic and unsystematic risks associated with investing in Adverum Biotechnologies over a specified time horizon. Remember, high Adverum Biotechnologies' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Adverum Biotechnologies' market risk premium analysis include:
Beta (1.23) | Alpha 0.54 | Risk 3.7 | Sharpe Ratio (0.09) | Expected Return (0.32) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. Adverum Biotechnologies Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Adverum Biotechnologies market risk premium is the additional return an investor will receive from holding Adverum Biotechnologies long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Adverum Biotechnologies. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Adverum Biotechnologies' performance over market.| α | 0.54 | β | -1.23 |
Adverum Biotechnologies Fundamentals Vs Peers
Comparing Adverum Biotechnologies' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Adverum Biotechnologies' direct or indirect competition across all of the common fundamentals between Adverum Biotechnologies and the related equities. This way, we can detect undervalued stocks with similar characteristics as Adverum Biotechnologies or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Adverum Biotechnologies' fundamental indicators could also be used in its relative valuation, which is a method of valuing Adverum Biotechnologies by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Adverum Biotechnologies to competition |
| Fundamentals | Adverum Biotechnologies | Peer Average |
| Return On Equity | -4.18 | -0.31 |
| Return On Asset | -0.77 | -0.14 |
| Current Valuation | 159.14 M | 16.62 B |
| Shares Outstanding | 22.08 M | 571.82 M |
| Shares Owned By Insiders | 13.21 % | 10.09 % |
| Shares Owned By Institutions | 88.30 % | 39.21 % |
| Number Of Shares Shorted | 811.4 K | 4.71 M |
Adverum Biotechnologies Opportunities
Adverum Biotechnologies Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Adverum Biotechnologies Completes Screening for Phase 3 Trial - MSN | 09/26/2025 |
2 | Lilly to Acquire Adverum Biotechnologies | 10/24/2025 |
3 | Volume spikes in Adverum Biotechnologies Inc. stock what they mean - 2025 Volume Leaders Growth Focused Entry Reports - newser.com | 11/13/2025 |
4 | Growth or Stability A 2025 Investment Face-Off Between LLY and JNJ | 11/17/2025 |
5 | What is HC Wainwrights Forecast for ADVM FY2025 Earnings | 11/19/2025 |
6 | Insider Trading | 11/25/2025 |
7 | Disposition of 51961 shares by Leonard Braden Michael of Adverum Biotechnologies at 4.2 subject to Rule 16b-3 | 12/02/2025 |
8 | Acquisition by Soparkar Peter of 50000 shares of Adverum Biotechnologies at 4.22 subject to Rule 16b-3 | 12/05/2025 |
9 | Acquisition by Laurent Fischer of 117614 shares of Adverum Biotechnologies at 4.31 subject to Rule 16b-3 | 12/08/2025 |
10 | Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition | 12/09/2025 |
About Adverum Biotechnologies Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Adverum or other stocks. Alpha measures the amount that position in Adverum Biotechnologies has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2024 | 2025 (projected) | Interest Debt Per Share | 1.84 | 4.64 | 4.87 | Revenue Per Share | 0.0621 | 0.0506 | 0.0322 |
Adverum Biotechnologies Upcoming Company Events
As portrayed in its financial statements, the presentation of Adverum Biotechnologies' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Adverum Biotechnologies' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Adverum Biotechnologies' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Adverum Biotechnologies. Please utilize our Beneish M Score to check the likelihood of Adverum Biotechnologies' management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Adverum Biotechnologies
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Adverum Biotechnologies technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.